Company: SMNR
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001193125-25-179226
Chunk: 146

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 146
---
| • |     | delays in obtaining approval from one or more IRBs; |

| • |     | IRBs refusing to approve, suspending or terminating the trial at the investigational site, precluding enrollment 
 of additional subjects, or withdrawing their approval of the trial;                                              |

| • |     | changes to the clinical trial protocol; |

| • |     | delays in recruiting suitable subjects to participate in our clinical trials; |

| • |     | failure by us, any CROs we engage or any other third parties to adhere to clinical trial requirements; |

| • |     | failure to perform in accordance with GCPs; |

| • |     | delays in the testing, validation, manufacturing and delivery of our product candidates to the clinical sites, 
 including delays by third parties with whom we have contracted to perform certain of those functions;          |

81

| • |     | delays in subjects completing participation in a trial or returning for post-treatment follow-up; |

| • |     | clinical trial sites or subjects dropping out of a trial; |

| • |     | key investigators departing their clinical sites; |

| • |     | lack of adequate funding to continue the trial; |

| • |     | selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the 
 resulting data;                                                                                           |

| • |     | subjects experiencing severe or unexpected drug-related adverse effects; |

| • |     | imposition of a clinical hold by regulatory authorities as a result of a serious adverse event, after an    
 inspection of our clinical trial operations, trial sites or manufacturing facilities, or for other reasons; |

| • |     | occurrence of serious adverse events (“SAEs”) in our trials or in trials of the same class of agents 
 conducted by other sponsors;                                                                         |

| • |     | changes in regulatory requirements or guidance that require amending or submitting new clinical protocols; |

| • |     | a facility manufacturing our product candidates or any of their components being ordered by the FDA to       
 temporarily or permanently shut down due to violations of cGMP regulations or other applicable requirements; |

| • |     | any changes to our manufacturing process that may be necessary or desired; |

| • |     | third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials and/or                                     
 not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, GCP, or other regulatory requirements; |

| • |     | third-party contractors not performing data